Nektar Therapeutics

NKTR

Market cap $1.93B

SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

The mean of analysts' price targets for Nektar (NKTR) points to an 89.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami. TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m.

Nektar Therapeutics (NKTR) is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. REZPEG's unique mechanism expands regulatory T cells, aiming for durable immune balance rather than rapid symptom suppression, like current IL4/13 inhibitors. While REZPEG's induction data was only moderate versus competitors, its maintenance data confirms the intended, differentiated mechanism of action.

SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L. Hauser, M.D.

SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar sold 7,637,931 shares of common stock in the offering, which includes 1,034,482 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and 293,103 pre-funded warrants.

Nektar stock has increased more than 100% within a week and has skyrocketed 1,000% from its 52-week low of $6.50, trading at around $71 as of February 13, 2026. The surge intensified following the company's release of 36-week maintenance data from the REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis.

SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar is selling 6,603,449 shares of common stock and 293,103 pre-funded warrants in the offering.

Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Nektar Therapeutics  (NASDAQ: NKTR) stock surged in premarket trading Wednesday after new long-term data showed its experimental eczema therapy delivered sustained and even deepening disease control through one year, strengthening its competitive positioning in the multibillion-dollar atopic dermatitis market.